192 related articles for article (PubMed ID: 25955539)
41. Impact of pretransplant minimal residual disease after cord blood transplantation for childhood acute lymphoblastic leukemia in remission: an Eurocord, PDWP-EBMT analysis.
Ruggeri A; Michel G; Dalle JH; Caniglia M; Locatelli F; Campos A; de Heredia CD; Mohty M; Hurtado JM; Bierings M; Bittencourt H; Mauad M; Purtill D; Cunha R; Kabbara N; Gluckman E; Labopin M; Peters C; Rocha V
Leukemia; 2012 Dec; 26(12):2455-61. PubMed ID: 22555150
[TBL] [Abstract][Full Text] [Related]
42. Favorable outcome in 20-year follow-up of children with very-low-risk ALL and minimal standard therapy, with special reference to TEL-AML1 fusion.
Kanerva J; Saarinen-Pihkala UM; Niini T; Riikonen P; Möttönen M; Mäkipernaa A; Salmi TT; Vettenranta K; Knuutila S
Pediatr Blood Cancer; 2004 Jan; 42(1):30-5. PubMed ID: 14752791
[TBL] [Abstract][Full Text] [Related]
43. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.
Sramkova L; Muzikova K; Fronkova E; Krejci O; Sedlacek P; Formankova R; Mejstrikova E; Stary J; Trka J
Pediatr Blood Cancer; 2007 Jan; 48(1):93-100. PubMed ID: 16521130
[TBL] [Abstract][Full Text] [Related]
44. Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia.
Forero-Castro M; Robledo C; Benito R; Bodega-Mayor I; Rapado I; Hernández-Sánchez M; Abáigar M; Maria Hernández-Sánchez J; Quijada-Álamo M; María Sánchez-Pina J; Sala-Valdés M; Araujo-Silva F; Kohlmann A; Luis Fuster J; Arefi M; de Las Heras N; Riesco S; Rodríguez JN; Hermosín L; Ribera J; Camos Guijosa M; Ramírez M; de Heredia Rubio CD; Barragán E; Martínez J; Ribera JM; Fernández-Ruiz E; Hernández-Rivas JM
Br J Cancer; 2017 Jul; 117(2):256-265. PubMed ID: 28557976
[TBL] [Abstract][Full Text] [Related]
45. [Evaluation of early response to treatment and its prognostic value in childhood acute lymphoblastic leukemia].
Cui L; Zhang RD; Gao C; Li WJ; Zhao XX; Zheng HY; Li ZG; Wu MY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):298-303. PubMed ID: 24762995
[TBL] [Abstract][Full Text] [Related]
46. Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia.
Paganin M; Zecca M; Fabbri G; Polato K; Biondi A; Rizzari C; Locatelli F; Basso G
Leukemia; 2008 Dec; 22(12):2193-200. PubMed ID: 18754029
[TBL] [Abstract][Full Text] [Related]
47. Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study.
Yeoh AE; Ariffin H; Chai EL; Kwok CS; Chan YH; Ponnudurai K; Campana D; Tan PL; Chan MY; Kham SK; Chong LA; Tan AM; Lin HP; Quah TC
J Clin Oncol; 2012 Jul; 30(19):2384-92. PubMed ID: 22614971
[TBL] [Abstract][Full Text] [Related]
48. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia.
Schmiegelow K; Forestier E; Hellebostad M; Heyman M; Kristinsson J; Söderhäll S; Taskinen M;
Leukemia; 2010 Feb; 24(2):345-54. PubMed ID: 20010622
[TBL] [Abstract][Full Text] [Related]
49. High white blood cell count at diagnosis of childhood acute lymphoblastic leukaemia: biological background and prognostic impact. Results from the NOPHO ALL-92 and ALL-2000 studies.
Vaitkevičienė G; Forestier E; Hellebostad M; Heyman M; Jonsson OG; Lähteenmäki PM; Rosthoej S; Söderhäll S; Schmiegelow K;
Eur J Haematol; 2011 Jan; 86(1):38-46. PubMed ID: 21077959
[TBL] [Abstract][Full Text] [Related]
50. Treatment of childhood acute lymphoblastic leukemia in central America: a lower-middle income countries experience.
Navarrete M; Rossi E; Brivio E; Carrillo JM; Bonilla M; Vasquez R; Peña A; Fu L; Martinez R; Espinoza CM; Lacayo LF; Rodriguez H; Batista R; Barr R; Howard SC; Ribeiro RC; Masera G; Biondi A; Conter V; Valsecchi MG
Pediatr Blood Cancer; 2014 May; 61(5):803-9. PubMed ID: 24376115
[TBL] [Abstract][Full Text] [Related]
51. Low expressions of ARS2 and CASP8AP2 predict relapse and poor prognosis in pediatric acute lymphoblastic leukemia patients treated on China CCLG-ALL 2008 protocol.
Cui L; Gao C; Zhang RD; Jiao Y; Li WJ; Zhao XX; Liu SG; Yue ZX; Zheng HY; Deng GR; Wu MY; Li ZG; Jia HT
Leuk Res; 2015 Feb; 39(2):115-23. PubMed ID: 25530566
[TBL] [Abstract][Full Text] [Related]
52. [The clinical significance of detecting minimal residual disease in acute childhood B-cell lymphoblastic leukemia with flow cytometry].
Zhang LP; Cheng YF; Liu GL; Lu AD; Liu YR; Wang H
Zhonghua Er Ke Za Zhi; 2005 Jul; 43(7):481-5. PubMed ID: 16083543
[TBL] [Abstract][Full Text] [Related]
53. Long-term results of Taiwan Pediatric Oncology Group studies 1997 and 2002 for childhood acute lymphoblastic leukemia.
Liang DC; Yang CP; Lin DT; Hung IJ; Lin KH; Chen JS; Hsiao CC; Chang TT; Peng CT; Lin MT; Chang TK; Jaing TH; Liu HC; Wang LY; Yeh TC; Jou ST; Lu MY; Cheng CN; Sheen JM; Chiou SS; Wu KH; Hung GY; Chen RL; Chen SH; Cheng SN; Chang YH; Chen BW; Ho WL; Wang JL; Lin ST; Hsieh YL; Wang SC; Chang HH; Yang YL; Huang FL; Chang CY; Chang WH; Lin KS
Leukemia; 2010 Feb; 24(2):397-405. PubMed ID: 20016538
[TBL] [Abstract][Full Text] [Related]
54. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.
van Dongen JJ; Seriu T; Panzer-Grümayer ER; Biondi A; Pongers-Willemse MJ; Corral L; Stolz F; Schrappe M; Masera G; Kamps WA; Gadner H; van Wering ER; Ludwig WD; Basso G; de Bruijn MA; Cazzaniga G; Hettinger K; van der Does-van den Berg A; Hop WC; Riehm H; Bartram CR
Lancet; 1998 Nov; 352(9142):1731-8. PubMed ID: 9848348
[TBL] [Abstract][Full Text] [Related]
55. Survival outcome following isolated central nervous system relapse treated with additional chemotherapy and craniospinal irradiation in childhood acute lymphoblastic leukemia.
Kumar P; Kun LE; Hustu HO; Mulhern RK; Hancock ML; Coffey D; Rivera GK
Int J Radiat Oncol Biol Phys; 1995 Feb; 31(3):477-83. PubMed ID: 7852109
[TBL] [Abstract][Full Text] [Related]
56. Clinical features, early treatment responses, and outcomes of pediatric acute lymphoblastic leukemia in China with or without specific fusion transcripts: a single institutional study of 1,004 patients.
Gao C; Zhao XX; Li WJ; Cui L; Zhao W; Liu SG; Yue ZX; Jiao Y; Wu MY; Li ZG
Am J Hematol; 2012 Nov; 87(11):1022-7. PubMed ID: 22911440
[TBL] [Abstract][Full Text] [Related]
57. [Analysis of multicenter efficacy of acute lymphoblastic leukemia in older children].
Jiang H; Tang JY; Zhang N; Sun LR; Yuan XJ; Wang NL
Zhonghua Xue Ye Xue Za Zhi; 2013 Jul; 34(7):581-6. PubMed ID: 23906450
[TBL] [Abstract][Full Text] [Related]
58. Prognostic role of minimal residual disease in mature B-cell acute lymphoblastic leukemia of childhood.
Mussolin L; Pillon M; Conter V; Piglione M; Lo Nigro L; Pierani P; Micalizzi C; Buffardi S; Basso G; Zanesco L; Rosolen A
J Clin Oncol; 2007 Nov; 25(33):5254-61. PubMed ID: 18024872
[TBL] [Abstract][Full Text] [Related]
59. [Clinical importance of minimal residual disease testing in the therapy of childhood B-cell acute lymphoblastic leukemia].
Ye QD; Gu LJ; Tang JY; Xue HL; Chen J; Pan C; Chen J; Dong L; Zhou M; Jiang LM
Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):333-6. PubMed ID: 18554462
[TBL] [Abstract][Full Text] [Related]
60. Clinical relevance of CD10 expression in childhood ALL. The Italian Association for Pediatric Hematology and Oncology (AIEOP).
Consolini R; Legitimo A; Rondelli R; Guguelmi C; Barisone E; Lippi A; Cantù-Rajnoldi A; Aricò M; Conter V; Cocito MG; Putti MC; Pession A; Masera G; Biondi A; Basso G
Haematologica; 1998 Nov; 83(11):967-73. PubMed ID: 9864914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
